ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
Home
Press release
Feb 22, 2021 13:11 JST
Source:
Eisai
Eisai Receives Corporate Philanthropy Award for Its Efforts to Realize Human Health Care (hhc) Philosophy
TOKYO, Feb 22, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received the 18th Corporate Philanthropy Award (FY 2020) of the Japan Philanthropic Association. The presentation ceremony was held on February 19, 2021 (Friday) at the GakushiKaikan (Chiyoda-ku, Tokyo).
Award ceremony (left: Ms. Yoko Takahashi, director, the Japan Philanthropic Association, right: Keigo Kato, executive director, Knowledge Creation Dept., Eisai)
The Corporate Philanthropy Award was founded in 2003 with the aim of commending companies for their activities for social contribution that organically and sustainably utilize their management resources (human resources, know-how, technology, information, etc.) in order to solve social issues, and of passing on a fair, warm and vibrant society to the next generation by broadly disseminating those social contribution activities to society.
The award was presented to Eisai for its corporate philosophy of human health care (hhc) and its activities to realize the hhc philosophy, evaluating "a corporate culture and purposeful activities where employees demonstrate their true value toward the realization of a society in which people can live happily."
Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides, and Eisai calls this philosophy the "human health care (hhc)" philosophy, in one word. In 2005, Eisai stipulated this philosophy as one of its Articles of Incorporation with the support of its shareholders. As an initiative to embody this hhc philosophy, Eisai recommends all officers and employees of the Eisai Group, including outside directors, to spend 1% of their business hours with patients and to engage in "socialization" to know their emotions. In addition, for developing and emerging countries, Eisai has continuously provided a treatment for lymphatic filariasis, which is one of the neglected tropical disease (NTDs), free of charge to endemic counties through the World Health Organization (WHO). Furthermore, Eisai has adopted the tiered-pricing model for its innovative new drugs, which sets multiple tiered prices according to the patient's income level and the insurance coverage that patients could afford. Thus, we are promoting various efforts to improve access to pharmaceutical products.
Eisai will make continuous efforts, based on the hhc philosophy, to further contribute to increasing the benefits of patients and their families around the world.
Source: Eisai
Sectors: BioTech
Copyright ©2021 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Mitsubishi Power Receives Order for Two Gas Turbines for 1,500MW Class GTCC Power Plant in Uzbekistan
Apr 14, 2021 15:36 JST
Honda to Introduce First Energy Service for Europe - e:PROGRESS - in the UK
Apr 14, 2021 15:11 JST
Eisai to Present Latest Data on Neurology Products and Pipelines at the American Academy of Neurology Annual Meeting
Apr 14, 2021 13:49 JST
Mazda3 Named Canadian Car of the Year 2021
Apr 14, 2021 12:47 JST
Tokyo Century and DOCOMO to Globally Expand EDGEMATRIX Edge-AI Platform for Video Surveillance & Monitoring
Apr 13, 2021 17:57 JST
Fujitsu Renews Key Systems for Japan Meteorological Agency, Contributing to Completion of Centralized Virtualization Platform
Apr 13, 2021 15:28 JST
NEC recognized as a Partner of the Year by Juniper Networks for two consecutive years
Apr 13, 2021 11:52 JST
Eisai: Animation Featuring Lymphatic Filariasis Elimination Activities Receives Animation Award at International Society for Neglected Tropical Diseases Festival 2021
Apr 12, 2021 13:16 JST
Fujitsu Embarks on Partnership with Siemens Digital Industries Software Strengthening Global Competitiveness and Accelerating DX to Realize Smart, Sustainable Manufacturing
Apr 12, 2021 11:48 JST
Lexus to Display LF-Z Electrified Concept and New ES
Apr 12, 2021 11:09 JST
MHI Invests in Starfire Energy, a Modular Green Ammonia Solution Provider, to Accelerate Efforts to Energy Transition
Apr 09, 2021 17:22 JST
DENSO Develops Advanced Driver Assistance Products for New Lexus LS, Toyota Mirai
Apr 09, 2021 13:46 JST
Deltacore Capital launches Deltacore Digital Global LP
Apr 09, 2021 13:30 JST
Hitachi Astemo to showcase advanced mobility solutions at Auto Shanghai 2021
Apr 09, 2021 13:05 JST
Overview of Honda and Acura Exhibits for Auto Shanghai 2021
Apr 08, 2021 15:25 JST
NEC and Cisco expand strategic partnership to help advance global deployments of 5G IP transport networks
Apr 08, 2021 14:26 JST
Toyota Launches LS and Mirai Equipped with "Advanced Drive" that Enables Drivers and Cars to Drive Together in Japan
Apr 08, 2021 13:40 JST
Fujitsu and Trend Micro Demonstrate Solution To Secure Private 5G
Apr 08, 2021 13:08 JST
DENSO Has Begun Testing CO2 Circulation Plant at Anjo Electrifica
Apr 07, 2021 17:24 JST
DENSO Transfers Its Aftermarket and Non-automotive Business to DENSO Solution
Apr 07, 2021 16:02 JST
More Latest Release >>
Related Release
Eisai to Present Latest Data on Neurology Products and Pipelines at the American Academy of Neurology Annual Meeting
April 14 2021 12:49 JST
Eisai: Animation Featuring Lymphatic Filariasis Elimination Activities Receives Animation Award at International Society for Neglected Tropical Diseases Festival 2021
April 12 2021 12:16 JST
KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries
March 31 2021 20:22 JST
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan
March 31 2021 20:18 JST
Eisai: European Medicines Agency Accepts the Marketing Authorisation Applications for Two Additional Indications of Anti Cancer Agent Lenvatinib in Combination with Pembrolizumab
March 30 2021 11:42 JST
Eisai: Discovery Research on AMPA-type Glutamate Receptor Antagonist Perampanel Honored With PSJ Award for Drug Research and Development 2021
March 26 2021 08:16 JST
Lenvima (Lenvatinib) Approved for Additional Indication of Unresectable Thymic Carcinoma in Japan
March 23 2021 17:34 JST
Eisai Begins Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan
March 22 2021 12:13 JST
Eisai Awarded The New Diversity Management Selection 100
March 22 2021 09:38 JST
DZNE and Eisai Enter Into Research Collaboration Agreement Aiming for Novel Drug Discovery for Neurodegenerative Disorders
March 17 2021 10:05 JST
More Press release >>